Collectively, these results indicate that VHL-null ccRCC cells are sensitized to sorafenib when combined with LONP1 inhibitor bortezomib, leading to a profound tumour growth defect in vivo that was associated with increased levels of mitochondrial content. The gene discussed is VHL; the disease is neoplasm.